Hem › Äggstockscancer › District of Columbia › Washington
Kliniska studier för Äggstockscancer i Washington, DC
23 studier för Äggstockscancer söker deltagare vid platser i och runt Washington (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekryterarFriska volontärer välkomna
- Walter Reed National Military Medical Center, Bethesda · 7 mi bort
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekryterarFas 2
- Walter Reed National Military Medical Center, Bethesda · 7 mi bort
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
RekryterarFas 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RekryterarFas 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RekryterarObservationsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RekryterarObservationsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RekryterarFas 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekryterarFas 2
- Holy Cross Hospital /ID# 275872, Silver Spring · 7 mi bort
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RekryterarFas 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
RekryterarFas 3
- MedStar Washington Hospital Center ( Site 0026), Washington D.C.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekryterarFas 1
- Georgetown University Medical Center, Washington D.C.
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekryterarFas 3
- Holy Cross Hospital, Silver Spring · 7 mi bort
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekryterarFas 2
- Medstar Georgetown University Hospital, Washington D.C.
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RekryterarFas 3
- Holy Cross Hospital, Silver Spring · 7 mi bort
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekryterarFas 1/2
- Children's National Medical Center, Washington D.C.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekryterarFas 1
- Normunity Investigational Site, Washington D.C.
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
RekryterarFas 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RekryterarFas 2
- USA11-0, Bethesda · 7 mi bort
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RekryterarFas 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RekryterarObservationsstudieFriska volontärer välkomna
- Cancer Support Community Research & Training Institute, Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi bort
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi bort
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
RekryterarFriska volontärer välkomna
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
RekryterarFas 1
- Holy Cross Hospital, Silver Spring · 7 mi bort
Äggstockscancer-studier i andra städer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
Andra studier i Washington
- Cancer (alla typer)58 studier
- Icke-småcellig lungcancer55 studier
- Bröstcancer46 studier
- Metastaserande cancer43 studier
- Lungcancer41 studier
- Prostatacancer38 studier
- Övervikt33 studier
- Kolorektal cancer29 studier
- Hjärt-kärlsjukdom28 studier
- Blåscancer26 studier
- Akut myeloid leukemi24 studier
- Lymfom23 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.